Kilitch Drugs (India) Limited Q2 FY26 results press release summary

Results press release of 14 Nov 2025, summarised by AI from the filing.

Management expects business momentum to remain positive in the second half of FY26.

Key takeaways

1. Guidance Management expects business momentum to remain positive in the second half of FY26.
2. Demand Sustained orders for parenteral range and increasing traction in oral solids and effervescent formulations.

Original filing on BSE

Kilitch Drugs (India) Limited Q1 FY27 results

As filed: Revenue ₹44.9 cr (+4% year on year), EBITDA ₹2.9 cr (−2% year on year), PAT ₹2.0 cr (−2% year on year), EBITDA margin 6.5% (−45 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

• Q4 FY26: Revenue ₹89.6 cr (+47% year on year), EBITDA ₹22.1 cr (+48% year on year), PAT ₹14.9 cr (+49% year on year), EBITDA margin 24.7% (+12 bps). Score 75 of 100, Above trend. Revenue growth was well above the company's own trend; EBITDA and profit growth were in line with it. EBITDA margin rose 12 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Revenue rose ₹28.6 cr on a year ago, more than the ₹16.0 cr it added the year before. Share price after the results: +23.0% in 28 days (Nifty 500: +0.3%).
• Q3 FY26: Revenue ₹53.8 cr (−4% year on year), EBITDA ₹6.2 cr (−23% year on year), PAT ₹4.3 cr (−28% year on year), EBITDA margin 11.5% (−284 bps). Score 26 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 284 bps year on year. Other income 27% of PBT. Profit fell 46% from last quarter. Share price after the results: −15.1% in 30 days (Nifty 500: −10.1%).
• Q2 FY26: Revenue ₹49.0 cr (+4% year on year), EBITDA ₹4.0 cr (−33% year on year), PAT ₹8.0 cr (−11% year on year), EBITDA margin 8.2% (−460 bps). Score 26 of 100, Below trend. Revenue, EBITDA and profit growth were below the company's own trend. EBITDA margin fell 460 bps year on year. Other income 78% of PBT. Share price after the results: −7.1% in 29 days (Nifty 500: −0.4%).
• Q1 FY26: Revenue ₹43.0 cr (+30% year on year), EBITDA ₹3.0 cr (+50% year on year), PAT ₹2.0 cr, EBITDA margin 7.0% (+92 bps). Score 49 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin rose 92 bps year on year. Other income 100% of PBT. Revenue fell 30% from last quarter. Share price after the results: −17.1% in 30 days (Nifty 500: +2.2%).
• Q4 FY25: Revenue ₹61.0 cr (+36% year on year), EBITDA ₹15.0 cr (+114% year on year), PAT ₹10.0 cr (+150% year on year), EBITDA margin 24.6% (+903 bps). Score 79 of 100, Above trend. Revenue and profit growth were above the company's own trend; EBITDA growth was well above it. EBITDA margin rose 903 bps year on year. Profit rose ₹6.0 cr on a year ago, more than the ₹1.0 cr it added the year before. Share price after the results: +2.7% in 30 days (Nifty 500: +0.3%).
• Q3 FY25: Revenue ₹56.0 cr (+75% year on year), EBITDA ₹8.0 cr (+167% year on year), PAT ₹6.0 cr (+200% year on year), EBITDA margin 14.3% (+491 bps). Score 85 of 100, Above trend. Revenue, EBITDA and profit growth were well above the company's own trend. EBITDA margin rose 491 bps year on year. Tax rate 38%. Profit fell 33% from last quarter.
• Q2 FY25: Revenue ₹47.0 cr (+15% year on year), EBITDA ₹6.0 cr (−40% year on year), PAT ₹9.0 cr (+80% year on year), EBITDA margin 12.8% (−1,000 bps). Score 39 of 100, Below trend. EBITDA margin fell 1000 bps year on year. Other income 50% of PBT. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Kilitch Drugs (India) Limited earnings call, investor presentation and press release summaries

• Q2 FY26: Results press release (14 Nov 2025)
• Q4 FY25: Results press release (22 May 2025)